CA2387394C - Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder - Google Patents

Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder Download PDF

Info

Publication number
CA2387394C
CA2387394C CA002387394A CA2387394A CA2387394C CA 2387394 C CA2387394 C CA 2387394C CA 002387394 A CA002387394 A CA 002387394A CA 2387394 A CA2387394 A CA 2387394A CA 2387394 C CA2387394 C CA 2387394C
Authority
CA
Canada
Prior art keywords
aminoindan
control
salt
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002387394A
Other languages
English (en)
French (fr)
Other versions
CA2387394A1 (en
Inventor
Gabriela Barak
Ruth Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2387394A1 publication Critical patent/CA2387394A1/en
Application granted granted Critical
Publication of CA2387394C publication Critical patent/CA2387394C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002387394A 1999-10-27 2000-10-27 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder Expired - Fee Related CA2387394C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16181799P 1999-10-27 1999-10-27
US60/161,817 1999-10-27
PCT/US2000/029618 WO2001030339A1 (en) 1999-10-27 2000-10-27 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

Publications (2)

Publication Number Publication Date
CA2387394A1 CA2387394A1 (en) 2001-05-03
CA2387394C true CA2387394C (en) 2009-08-18

Family

ID=22582876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387394A Expired - Fee Related CA2387394C (en) 1999-10-27 2000-10-27 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

Country Status (9)

Country Link
US (1) US6492426B1 (enExample)
EP (1) EP1242066B1 (enExample)
JP (1) JP2003512426A (enExample)
AT (1) ATE331508T1 (enExample)
AU (1) AU775885B2 (enExample)
CA (1) CA2387394C (enExample)
DE (1) DE60029131T2 (enExample)
IL (2) IL149308A0 (enExample)
WO (1) WO2001030339A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140090996A (ko) * 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
US9181026B2 (en) 2013-10-03 2015-11-10 Custom Chemical Solutions, LLC Containment berm with internal “L” braces
WO2024196698A2 (en) * 2023-03-17 2024-09-26 Curadh Mtr Compounds and constructs useful for targeting fibroblast activation protein

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852735A (en) 1956-04-13 1960-11-02 Schering Ag Manufacture of 1-aminoindanes
US3637740A (en) * 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
BE786748A (fr) * 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
US4096173A (en) * 1977-03-28 1978-06-20 Eli Lilly And Company Chlorinated 1-aminoindane N-methyl transferase inhibitors
JPS5824433A (ja) * 1981-08-06 1983-02-14 Takehiro Mokuzai Kogyo Kk 繊維材成型品の表面化粧方法
SE464194B (sv) 1983-03-04 1991-03-18 Otsuka Pharma Co Ltd Indanderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner
EP0173331B1 (en) 1984-08-31 1991-08-14 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1h-indene derivatives, a process for preparing them and pharmaceutical compositions containing same
US5242919A (en) 1984-08-31 1993-09-07 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1H-indene derivatives
JPS6169747A (ja) 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法
US4882339A (en) 1987-07-10 1989-11-21 Ciba-Geigy Corporation 4-Amino-substituted 1,2-dihydroxynaphthalene derivatives useful in inhibiting 5-lipoxygenase activity in mammals
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5344836A (en) 1991-11-11 1994-09-06 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives
CH683996A5 (fr) 1992-03-05 1994-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et compositions pharmaceutiques les contenant.
KR100238346B1 (ko) 1993-04-07 2000-03-02 오쓰까 아끼히꼬 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
US5646188A (en) 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5887218A (en) 1996-06-10 1999-03-23 Ricoh Co., Ltd. Color image forming apparatus having toner and transfer sheet bearing members and image forming method thereof
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO1998055447A1 (en) 1997-06-05 1998-12-10 Venantius Limited 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
US5887221A (en) 1997-10-20 1999-03-23 Xerox Corporation Signature sensing for optimum toner control with donor roll
US6227886B1 (en) 1999-04-16 2001-05-08 Avaya Technology Corp. Snag-resistant patchcord plug latch and cover

Also Published As

Publication number Publication date
JP2003512426A (ja) 2003-04-02
EP1242066A4 (en) 2004-09-01
CA2387394A1 (en) 2001-05-03
AU1440201A (en) 2001-05-08
IL149308A0 (en) 2002-11-10
EP1242066B1 (en) 2006-06-28
WO2001030339A1 (en) 2001-05-03
IL149308A (en) 2007-07-24
DE60029131D1 (de) 2006-08-10
US6492426B1 (en) 2002-12-10
ATE331508T1 (de) 2006-07-15
EP1242066A1 (en) 2002-09-25
AU775885B2 (en) 2004-08-19
DE60029131T2 (de) 2007-01-18

Similar Documents

Publication Publication Date Title
JP4782252B2 (ja) １−アミノインダン及びこれらの組成物
US20100256145A1 (en) Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8883808B2 (en) Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
JP5024635B2 (ja) 睡眠覚醒障害の治療
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
KR20010024076A (ko) 5-ＨＴ 재흡수 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는 부분작용제의 배합물
US20120046302A1 (en) Methods of treating cns disorders
KR101500962B1 (ko) 정신 장애의 치료에 유용한 알파­아미노아미드 유도체
CA2387394C (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
US20050119285A1 (en) Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists
JPWO2004060400A1 (ja) 上皮成長因子受容体を分子標的とする抗精神病薬
WO2010126527A1 (en) Methods of treating cns disorders
CN112367998B (zh) 用组胺-3受体反向激动剂进行治疗的方法
Tortella et al. EEG seizure activity and behavioral neurotoxicity produced by (+)-MK801, but not the glycine site antagonist L-687,414, in the rat
CA2814828A1 (en) Method of treatment for mental disorders
JP2011088919A (ja) アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
US20040254173A1 (en) Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
Dwivedi et al. Overview Central & Peripheral Nervous Systems: Anti-epileptic agents: recent developments
RU2007128964A (ru) Антагонисты рецепторов 5-ht7
RS4504A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola u vezi sa klasterskim i migrenskim glavoboljama
BR112020024264B1 (pt) Uso de um agonista inverso do receptor de histamina-3 para a fabricação de um medicamento e uso de uma composição farmacêutica
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1153672A (en) Amines and amides for the treatment of diseases
RU2007109791A (ru) Антагонисты 5-нт7 рецепторов

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed